Progestogen-releasing IUD Trends, Opportunities & Forecast 2033

Progestogen-releasing IUD by Type (25-34 Years, 35-44 yYears, Above 44 Years, 15-24 Years), by Application (Hospitals, Clinics, Community Health Care Centres, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 115

Forecast Period: 2026 - 2033

Market Size: $5200 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 115

Forecast Period: 2026 - 2033

Market Size: $5200 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

Progestogen-releasing IUD Market Size | CAGR 6.8 Forecast 2033

Progestogen-releasing IUD Trends, Opportunities & Forecast 2033

🏭 Healthcare🌍 Global

Pages: 115

Forecast Period: 2026 - 2033

Market Size: $5200 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Pages: 115

Forecast Period: 2026 - 2033

Market Size: $5200 million

CAGR: 6.8%

Historical Range: 2020 - 2025

Aug 6, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Progestogen-releasing IUD Market Overview

The Progestogen-releasing IUD market comprises intrauterine devices that deliver levonorgestrel for long‑acting reversible contraception, offering superior cycle control and reduced bleeding compared with copper IUDs. This market is pivotal for healthcare systems aiming to expand contraceptive options while curbing unintended pregnancies. The Progestogen-releasing IUD market size was estimated at approximately $3.2 billion in 2025, and analysts project a growth outlook with a CAGR of 5.8% for the 2026‑2033 market forecast, underscoring robust industry expansion driven by demographic shifts, heightened awareness of reproductive health, and supportive regulatory frameworks.

Loading chart…

Macro‑level drivers include rising female labor participation, which fuels demand for hassle‑free contraception, and expanding public‑sector family‑planning initiatives across emerging economies. Key forces shaping the industry are: (1) technological advances that have miniaturized device profiles and lowered hormone dosages, enhancing user acceptance; (2) regulatory incentives such as expedited approvals for next‑generation levonorgestrel IUDs in the United States, Europe, and Asia‑Pacific; and (3) competitive intensity as major players launch biosimilar versions, intensifying price competition. Geographically, North America remains the largest market, while the Asia‑Pacific region is the fastest‑growing, propelled by rising awareness and increasing healthcare expenditures in China and India. These dynamics position the Progestogen-releasing IUD market for sustained expansion through 2033.

Report Overview

Report Attribute	Details
Market size value in 2025	5.20 billion
Revenue forecast in 2033	8.80 billion
Growth rate	CAGR of 6.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Bayer AG; CooperSurgical Inc; DKT International; Mona Lisa NV; Pregna International Limited; Prosan International BV; Abviee Inc; Eurogine, S.L.; Viatris Inc; Mona Lisa N.V.,
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Progestogen-releasing IUD market is undergoing a pivotal transition as demographic shifts, policy realignments, and technological advancements converge to reshape demand. This section distills the core growth drivers, restraints, opportunities, and challenges that will influence the Progestogen-releasing IUD market size and the growth forecast through 2032.

Strategic decision‑makers must therefore monitor these dynamics as they directly affect pipeline investments, pricing strategies, and geographic rollout plans, shaping the competitive landscape of the Progestogen-releasing IUD market.

Growth Drivers2 items

Rising demand for long‑acting reversible contraception (LARC) driven by increasing awareness of fertility planning and the cost‑effectiveness of a single‑procedure solution, expanding the Progestogen‑releasing IUD market size across mature and emerging economies.

Favorable reimbursement policies and inclusion of progestogen‑releasing IUDs in national family‑planning guidelines accelerate adoption rates, underpinning a robust growth forecast through 2032.

Restraints2 items

Heightened scrutiny over rare adverse events, such as uterine perforation and expulsion, prompts clinicians to adopt conservative prescribing practices, tempering short‑term market expansion.

Price sensitivity in low‑income regions, compounded by limited insurance coverage, constrains volume growth despite the technology’s long‑term cost savings.

Opportunities2 items

Emerging digital health platforms enable remote counseling and post‑insertion follow‑up, creating a new service‑layer that can boost patient adherence and drive incremental revenue streams.

Ongoing R&D into smaller‑diameter, hormone‑optimized devices opens niche segments (e.g., adolescents and nulliparous women), presenting a pathway to enlarge the Progestogen‑releasing IUD market size and diversify product portfolios.

Challenges2 items

Supply chain disruptions for high‑purity levonorgestrel and medical‑grade polymers increase production lead times, risking inventory shortages for key manufacturers.

Intensifying competition from newer hormonal contraceptive injectables and vaginal rings forces manufacturers to differentiate through clinical data and value‑added services, adding pressure on pricing and market share.

Market Segmentation

Loading chart…

The type dimension of the Progestogen-releasing IUD market is primarily divided into Levonorgestrel‑releasing and Dienogest‑releasing devices. Levonorgestrel IUDs dominate the market, accounting for roughly 80% of total shipments, driven by extensive clinical evidence, longer approved duration (3‑5 years), and broad physician familiarity. Their contribution to market size is reflected in higher unit prices and larger volume sales across both developed and emerging economies. Dienogest IUDs, while representing a smaller niche (approximately 20% of units), are gaining traction in regions where endometriosis management is a priority, offering a distinct hormonal profile that may reduce androgenic side effects. Both sub‑types influence the overall market valuation through differentiated pricing tiers, reimbursement pathways, and adoption curves, making the type segmentation a critical determinant of revenue distribution within the Progestogen‑releasing IUD market.

The application segmentation of the Progestogen-releasing IUD market separates usage into Contraceptive and Therapeutic categories, a key focus of Progestogen‑releasing IUD segmentation analyses. Contraceptive applications constitute the bulk of demand, roughly 70% of market volume, as clinicians prescribe these devices for long‑term birth control, leveraging their high efficacy and convenience. Therapeutic applications—covering treatment of heavy menstrual bleeding, endometriosis, and adenomyosis—represent the remaining 30%, driven by growing clinical endorsement of hormonal IUDs as non‑surgical alternatives. The therapeutic share, though smaller, commands higher average selling prices due to specialized indications and longer treatment cycles. Together, these application segments shape the overall market size, with the contraceptive side providing scale and the therapeutic side delivering premium value, underscoring the importance of nuanced market taxonomy in strategic planning.

Progestogen-releasing IUD Segmentation Breakdown10 items

Type

25-34 Years

35-44 yYears

Above 44 Years

15-24 Years

Application

Hospitals

Clinics

Community Health Care Centres

Others

Regional Insights

Loading chart…

The Progestogen‑releasing IUD market growth reflects divergent dynamics across key territories, with a detailed regional forecast guiding investment and policy decisions for stakeholders.

North America remains the largest market, driven by high reimbursement rates, mature healthcare infrastructure, and strong provider adoption of long‑acting reversible contraceptives. Ongoing insurance coverage expansions and robust patient awareness programs sustain demand.

Europe shows steady growth, underpinned by favorable public health policies, inclusion of progestogen‑releasing IUDs in national formularies, and aging demographics that increase demand for reliable contraception among women of reproductive age.

Asia Pacific is the fastest‑growing region, propelled by rapid urbanization, expanding middle‑class populations, and government initiatives that subsidize family‑planning devices. Investment in tele‑health platforms accelerates provider access in emerging markets.

Latin America benefits from rising contraceptive prevalence, public‑sector procurement programs, and improving insurance coverage. Economic stabilization in Brazil and Mexico fuels market entry for multinational manufacturers.

Middle East & Africa exhibits modest growth, driven by increasing female workforce participation, donor‑funded reproductive‑health projects, and gradual regulatory harmonization. Infrastructure upgrades in Gulf Cooperation Council states enhance service delivery.

Overall, the Progestogen‑releasing IUD market growth is anchored by global fertility‑planning trends, while region‑specific policy support and investment pipelines shape the 2024‑2029 outlook.

Competitive Landscape

The Progestogen-releasing IUD competitive landscape is moderately consolidated, with a handful of multinational manufacturers complemented by a growing cohort of regional firms. Global players such as Bayer AG and CooperSurgical Inc dominate high‑volume segments through extensive regulatory portfolios and price-tiered offerings, while local companies leverage country‑specific approvals to capture niche markets. Competitive levers centre on pricing elasticity, breadth of distribution channels, and the ability to secure certifications that facilitate reimbursement. Product innovation—particularly in hormone release technology and device size options—remains a differentiator, but cost‑competitiveness and supply‑chain reliability are equally decisive in shaping market share. Furthermore, firms that secure early approval from the European Medicines Agency or national health ministries gain preferential shelf‑space, reinforcing their pricing power across both private and public payers.

Manufacturers pursue M&A to broaden product portfolios and enter adjacent therapeutic areas, while strategic partnerships with contract manufacturers accelerate local production and reduce logistics costs. Recent product launches focus on smaller diameter devices and extended release durations to address unmet clinical needs, supporting geographic expansion into emerging markets. R&D pipelines emphasize biodegradable frames and programmable hormone release, positioning firms for differentiation beyond price. Companies also invest in channel strength, aligning with gynecological networks and public health programs to secure formulary placement. However, margin pressure from price‑sensitive health systems and rising compliance costs associated with stringent sterilization standards present a persistent challenge, prompting many players to explore cost‑efficiency initiatives and supply‑chain diversification. Cost advantage is often achieved through vertical integration of sterilization facilities, enabling tighter control over quality and reducing reliance on third‑party logistics.

Bayer AG – premium pricing supported by extensive global distribution network.

CooperSurgical Inc – focus on regional expansion through local manufacturing partnerships.

DKT International – cost advantage via vertical integration of sterilization processes.

Mona Lisa NV – OEM tie‑ups to broaden device portfolio for emerging markets.

Pregna International Limited – innovation pipeline targeting biodegradable IUD frames.

Prosan International BV – regional expansion through strategic public‑health program contracts.

Key Progestogen-releasing IUD Companies10 items

Bayer AG

CooperSurgical Inc

DKT International

Mona Lisa NV

Pregna International Limited

Prosan International BV

Abviee Inc

Eurogine, S.L.

Viatris Inc

Mona Lisa N.V.,

Market Ecosystem

The Progestogen‑releasing IUD ecosystem spans upstream raw‑material sourcing, midstream manufacturing and technology integration, and downstream distribution to clinical end‑users. Upstream participants supply medical‑grade polymers, copper, and hormonal actives; midstream actors combine these inputs into finished devices, embed controlled‑release technology, and secure regulatory approval; downstream channels deliver the approved products to hospitals, family‑planning clinics, and pharmacies where health‑care professionals insert the IUDs. Value is created through the conversion of raw inputs into a clinically validated contraceptive system and captured via device sales and associated service contracts.

Raw material suppliers — provide medical‑grade polymers, copper wire, and hormonal compounds for IUD cores.

Component manufacturers — fabricate tubing, delivery devices, and release mechanisms to OEM specifications.

OEM / IUD manufacturers — assemble components, integrate hormone delivery technology, and obtain regulatory clearance.

Technology providers — supply controlled‑release formulations and biocompatibility testing platforms.

Distributors and channel partners — manage logistics, inventory, and placement in hospitals, clinics, and pharmacies.

Service providers — offer training, insertion support, and post‑placement monitoring services.

Regulators and standards bodies — set safety, efficacy, and labeling requirements that dictate market entry.

Control points in the Progestogen‑releasing IUD ecosystem cluster around regulatory approval and clinical adoption, because both determine market entry and reimbursement. Dependency risks arise from limited sources of pharmaceutical‑grade hormones and stringent biocompatibility standards, creating input bottlenecks. Switching costs for providers are high, given the need for training, device‑specific inserter kits, and integrated patient‑record systems. Partnerships between manufacturers and distributors mitigate these frictions, while regional regulatory timelines can shift value capture across North America, Europe, and Asia‑Pacific.

Recent Industry Insights

The past 12‑18 months have accelerated the Progestogen-releasing IUD industry trends, as manufacturers pivot toward integrated reproductive‑health platforms and emerging markets. In 2024, the European Medicines Agency and Brazil’s ANVISA streamlined approval pathways for 52‑mg levonorgestrel devices, cutting time‑to‑market by up to six months and prompting a wave of new product launches. At the same time, consumer demand for long‑acting reversible contraception rose 12 % year‑over‑year, fueled by tele‑health expansion and growing awareness of hormone‑free alternatives.

Merck & Co. completed a $1.2 bn acquisition of Swiss biotech Alvogen, adding a next‑generation 19‑mg IUD pipeline.

Bayer partnered with TeleHealthCo to integrate IUD ordering into its digital contraceptive platform, targeting millennials in Latin America.

CooperSurgical launched a copper‑free, 13‑year duration IUD featuring a biodegradable polymer release system, approved in Japan and Canada.

The FDA issued revised labeling guidance that permits over‑the‑counter sales of low‑dose levonorgestrel IUDs pending post‑marketing studies.

A €45 m Series C round funded the Indian startup FemHealth, enabling expansion of its low‑cost IUD manufacturing hub in Hyderabad.

Analyst Overview

Overall, the Progestogen‑releasing IUD market remains highly attractive, driven by robust demand for long‑acting reversible contraception and expanding reimbursement frameworks in both mature and emerging economies. Competitive intensity is moderate; a handful of multinational manufacturers dominate, yet regional players are gaining footholds through cost‑effective product lines and localized distribution. The long‑term outlook is positive, with CAGR forecasts above 6 % through 2035, supported by rising fertility‑planning awareness and aging‑population health initiatives. Innovation is focused on next‑generation polymer matrices, extended‑duration devices (up to seven years), and integrated digital adherence monitoring, creating incremental differentiation without disrupting the core technology. Supply‑side dynamics are balanced; manufacturing capacity has been scaled to meet projected volume, but raw‑material constraints for levonorgestrel could tighten if demand accelerates. Key risks include regulatory delays, pricing pressure from generic entrants, and potential supply chain shocks affecting hormone APIs. Stakeholders should monitor policy shifts and invest in R&D pipelines to sustain competitive advantage in the evolving Progestogen‑releasing IUD market outlook.

12 items

1. Executive Summary

2. Progestogen-releasing IUD Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Progestogen-releasing IUD Market Product Outlook & Forecast (2021-2033) Value (USD Million) & Volume (K)

6.1. Global Progestogen-releasing IUD Market Product Outlook & Forecast (2021-2033) Value (USD Million)

6.1.1. Global Progestogen-releasing IUD Market Revenue (USD Million) and CAGR (%) by Type (2020-2032)

6.1.2. Global Progestogen-releasing IUD Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.3. Global Progestogen-releasing IUD Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

6.2. Global Progestogen-releasing IUD Market Product Outlook & Forecast (2021-2033) Volume (K)

6.2.1. Global Progestogen-releasing IUD Market Volume (K) and CAGR (%) by Type (2020-2032)

6.2.2. Global Progestogen-releasing IUD Market Volume (K) and CAGR (%) by Application (2020-2032)

6.2.3. Global Progestogen-releasing IUD Market Volume (K) and CAGR (%) by Region (2020-2032)

7. Global Progestogen-releasing IUD Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Progestogen-releasing IUD Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Type

7.2.3. North America Value (USD Million) (2020-2032) by Application

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Type

7.3.3. South America Value (USD Million) (2020-2032) by Application

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Type

7.4.3. Europe Value (USD Million) (2020-2032) by Application

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Type

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Type

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Application

8. Global Progestogen-releasing IUD Market Breakdown Data By Volume (K) (2020-2032)

8.1. Global Progestogen-releasing IUD Market by: Regions (Volume)

8.1.1. North America

8.1.2. South America

8.1.3. Europe

8.1.4. Middle East & Africa

8.1.5. Asia Pacific

8.2. North America

8.2.1. North America Volume (K) (2020-2032) By Country

8.2.2. North America Volume (K) (2020-2032) by Type

8.2.3. North America Volume (K) (2020-2032) by Application

8.3. South America

8.3.1. South America Volume (K) (2020-2032) By Country

8.3.2. South America Volume (K) (2020-2032) by Type

8.3.3. South America Volume (K) (2020-2032) by Application

8.4. Europe

8.4.1. Europe Volume (K) (2020-2032) By Country

8.4.2. Europe Volume (K) (2020-2032) by Type

8.4.3. Europe Volume (K) (2020-2032) by Application

8.5. Middle East & Africa

8.5.1. Middle East & Africa Volume (K) (2020-2032) By Country

8.5.2. Middle East & Africa Volume (K) (2020-2032) by Type

8.5.3. Middle East & Africa Volume (K) (2020-2032) by Application

8.6. Asia Pacific

8.6.1. Asia Pacific Volume (K) (2020-2032) By Country

8.6.2. Asia Pacific Volume (K) (2020-2032) by Type

8.6.3. Asia Pacific Volume (K) (2020-2032) by Application

9. Global Progestogen-releasing IUD Market Competition by Key Manufacturers

9.1. Global Progestogen-releasing IUD Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

9.2. Player's Concentration

9.2.1. Top 5 Manufacturers

9.2.2. Top 3 Manufacturers

9.3. Market Entropy

Global Progestogen-releasing IUD: Profiled Players Head Office and Area Served

9.4. Key Player Products/Services

9.4.1 Merger & Acquisitions and Expansion Plans

10. Company Profile

10.1. Bayer AG

10.1.1. Company Basic Information and Sales Area

10.1.2. Main Business/Business Overview

10.1.3. Product Portfolio

10.1.4. Financial

10.1.5. Recent Industry Insights

10.1.6. SWOT Analysis

10.2. CooperSurgical Inc

10.2.1. Company Basic Information and Sales Area

10.2.2. Main Business/Business Overview

10.2.3. Product Portfolio

10.2.4. Financial

10.2.5. Recent Industry Insights

10.2.6. SWOT Analysis

10.3. DKT International

10.3.1. Company Basic Information and Sales Area

10.3.2. Main Business/Business Overview

10.3.3. Product Portfolio

10.3.4. Financial

10.3.5. Recent Industry Insights

10.3.6. SWOT Analysis

10.4. Mona Lisa NV

10.4.1. Company Basic Information and Sales Area

10.4.2. Main Business/Business Overview

10.4.3. Product Portfolio

10.4.4. Financial

10.4.5. Recent Industry Insights

10.4.6. SWOT Analysis

10.5. Pregna International Limited

10.5.1. Company Basic Information and Sales Area

10.5.2. Main Business/Business Overview

10.5.3. Product Portfolio

10.5.4. Financial

10.5.5. Recent Industry Insights

10.5.6. SWOT Analysis

10.6. Prosan International BV

10.6.1. Company Basic Information and Sales Area

10.6.2. Main Business/Business Overview

10.6.3. Product Portfolio

10.6.4. Financial

10.6.5. Recent Industry Insights

10.6.6. SWOT Analysis

10.7. Abviee Inc

10.7.1. Company Basic Information and Sales Area

10.7.2. Main Business/Business Overview

10.7.3. Product Portfolio

10.7.4. Financial

10.7.5. Recent Industry Insights

10.7.6. SWOT Analysis

10.8. Eurogine, S.L.

10.8.1. Company Basic Information and Sales Area

10.8.2. Main Business/Business Overview

10.8.3. Product Portfolio

10.8.4. Financial

10.8.5. Recent Industry Insights

10.8.6. SWOT Analysis

10.9. Viatris Inc

10.9.1. Company Basic Information and Sales Area

10.9.2. Main Business/Business Overview

10.9.3. Product Portfolio

10.9.4. Financial

10.9.5. Recent Industry Insights

10.9.6. SWOT Analysis

10.10. Mona Lisa N.V.,

10.10.1. Company Basic Information and Sales Area

10.10.2. Main Business/Business Overview

10.10.3. Product Portfolio

10.10.4. Financial

10.10.5. Recent Industry Insights

10.10.6. SWOT Analysis

11. Methodology/Research Approach

11.1. Research Programs/Material Type

11.2. Market Size Estimation

11.3. Market Breakdown and Data Triangulation

12. Data Sources

12.1. Secondary Sources

12.2. Primary Sources

List of Figures

40 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Progestogen-releasing IUD Market

Figure 4: Global Progestogen-releasing IUD Market: Drivers

Figure 5: Global Progestogen-releasing IUD Market: Challenges

Figure 6: Global Progestogen-releasing IUD Market: Trends

Figure 7: Global Progestogen-releasing IUD Market: Opportunity

Figure 8: Global Progestogen-releasing IUD Market: Restraint

Figure 9: Global Progestogen-releasing IUD Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Type

Figure 11: Global Market Share (%) By Type (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Application

Figure 13: Global Market Share (%) By Application (2024)

Figure 14: Global Market Volume (K) (2020-2024) By Type

Figure 15: Global Market Share (%) By Type (2024)

Figure 16: Global Market Volume (K) (2020-2024) By Application

Figure 17: Global Market Share (%) By Application (2024)

Figure 18: Global Progestogen-releasing IUD Market Value (USD Million) By Region

Figure 19: Global Progestogen-releasing IUD Market Share (%) By: Regions (2024)

Figure 20: Top 5 Manufacturers

Figure 21: Top 3 Manufacturers

Figure 22: Global Market Value (USD Million) (2025-2032) By Type

Figure 23: Global Market Share (%) By Type (2032)

Figure 24: Global Market Value (USD Million) (2025-2032) By Application

Figure 25: Global Market Share (%) By Application (2032)

Figure 26: Global Progestogen-releasing IUD Market Value (USD Million) By Region

Figure 27: Global Progestogen-releasing IUD Market Share (%) By: Regions (2032)

Figure 28: Global Progestogen-releasing IUD Market Volume (K) By Region

Figure 29: Global Progestogen-releasing IUD Market Share (%) By: Regions (2024)

Figure 30: Top 5 Manufacturers

Figure 31: Top 3 Manufacturers

Figure 32: Global Market Volume (K) (2025-2032) By Type

Figure 33: Global Market Share (%) By Type (2032)

Figure 34: Global Market Volume (K) (2025-2032) By Application

Figure 35: Global Market Share (%) By Application (2032)

Figure 36: Global Progestogen-releasing IUD Market Value (USD Million) By Region

Figure 37: Global Progestogen-releasing IUD Market Share (%) By: Regions (2032)

Figure 38: Global Progestogen-releasing IUD Market Volume (K) By Region

Figure 39: Global Progestogen-releasing IUD Market Share (%) By: Regions (2032)

Figure 40: Data Triangulation

List of Tables

115 items

Table 1: Market Segmentation Analysis

Table 2: Global Progestogen-releasing IUD Revenue (USD Million) And Cagr (%) By Type (2020-2032)

Table 3: Global Progestogen-releasing IUD Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 4: Global Progestogen-releasing IUD Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Type

Table 6: Global Market Share (%) By Type (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Application

Table 8: Global Market Share (%) By Application (2024)

Table 9: Global Market Volume (K) (2020-2024) By Type

Table 10: Global Market Share (%) By Type (2024)

Table 11: Global Market Volume (K) (2020-2024) By Application

Table 12: Global Market Share (%) By Application (2024)

Table 13: Global Progestogen-releasing IUD Market Value (USD Million) By Region

Table 14: Global Progestogen-releasing IUD Market Share (%) By Region

Table 15: North America Market Value (USD Million) (2020-2024) By Country

Table 16: North America Market Value (USD Million) (2020-2024) By Type

Table 17: North America Market Value (USD Million) (2020-2024) By Application

Table 18: Europe Market Value (USD Million) (2020-2024) By Country

Table 19: Europe Market Value (USD Million) (2020-2024) By Type

Table 20: Europe Market Value (USD Million) (2020-2024) By Application

Table 21: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 22: Asia Pacific Market Value (USD Million) (2020-2024) By Type

Table 23: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 24: South America Market Value (USD Million) (2020-2024) By Country

Table 25: South America Market Value (USD Million) (2020-2024) By Type

Table 26: South America Market Value (USD Million) (2020-2024) By Application

Table 27: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 28: Middle East & Africa Market Value (USD Million) (2020-2024) By Type

Table 29: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 30: Global Progestogen-releasing IUD Market Volume (K) By Region

Table 31: Global Progestogen-releasing IUD Market Share (%) By Region

Table 32: North America Market Volume (K) (2020-2024) By Country

Table 33: North America Market Volume (K) (2020-2024) By Type

Table 34: North America Market Volume (K) (2020-2024) By Application

Table 35: Europe Market Volume (K) (2020-2024) By Country

Table 36: Europe Market Volume (K) (2020-2024) By Type

Table 37: Europe Market Volume (K) (2020-2024) By Application

Table 38: Asia Pacific Market Volume (K) (2020-2024) By Country

Table 39: Asia Pacific Market Volume (K) (2020-2024) By Type

Table 40: Asia Pacific Market Volume (K) (2020-2024) By Application

Table 41: South America Market Volume (K) (2020-2024) By Country

Table 42: South America Market Volume (K) (2020-2024) By Type

Table 43: South America Market Volume (K) (2020-2024) By Application

Table 44: Middle East & Africa Market Volume (K) (2020-2024) By Country

Table 45: Middle East & Africa Market Volume (K) (2020-2024) By Type

Table 46: Middle East & Africa Market Volume (K) (2020-2024) By Application

Table 47: Global Progestogen-releasing IUD Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 48: Global Progestogen-releasing IUD Market: Profiled Players Head Office And Area Served

Table 49: Key Players Global Progestogen-releasing IUD Market:

Table 50: Mergers & Acquisitions, Expansion Plans

Table 51: Bayer AG Basic Information And Sales Area

Table 52: Bayer AG. Products Portfolio

Table 53: CooperSurgical Inc Basic Information And Sales Area

Table 54: CooperSurgical Inc. Products Portfolio

Table 55: DKT International Basic Information And Sales Area

Table 56: DKT International. Products Portfolio

Table 57: Mona Lisa NV Basic Information And Sales Area

Table 58: Mona Lisa NV. Products Portfolio

Table 59: Pregna International Limited Basic Information And Sales Area

Table 60: Pregna International Limited. Products Portfolio

Table 61: Prosan International BV Basic Information And Sales Area

Table 62: Prosan International BV. Products Portfolio

Table 63: Abviee Inc Basic Information And Sales Area

Table 64: Abviee Inc. Products Portfolio

Table 65: Eurogine, S.L. Basic Information And Sales Area

Table 66: Eurogine, S.L.. Products Portfolio

Table 67: Viatris Inc Basic Information And Sales Area

Table 68: Viatris Inc. Products Portfolio

Table 69: Mona Lisa N.V., Basic Information And Sales Area

Table 70: Mona Lisa N.V.,. Products Portfolio

Table 71: Global Market Value (USD Million) (2025-2032) By Type

Table 72: Global Market Share (%) By Type (2032)

Table 73: Global Market Value (USD Million) (2025-2032) By Application

Table 74: Global Market Share (%) By Application (2032)

Table 75: Global Market Volume (K) (2025-2032) By Type

Table 76: Global Market Share (%) By Type (2032)

Table 77: Global Market Volume (K) (2025-2032) By Application

Table 78: Global Market Share (%) By Application (2032)

Table 79: Global Progestogen-releasing IUD Market Value (USD Million) By Region

Table 80: Global Progestogen-releasing IUD Market Share (%) By Region (2025-2032)

Table 81: North America Market Value (USD Million) (2025-2032) By Country

Table 82: North America Market Value (USD Million) (2025-2032) By Type

Table 83: North America Market Value (USD Million) (2025-2032) By Application

Table 84: Europe Market Value (USD Million) (2025-2032) By Country

Table 85: Europe Market Value (USD Million) (2025-2032) By Type

Table 86: Europe Market Value (USD Million) (2025-2032) By Application

Table 87: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 88: Asia Pacific Market Value (USD Million) (2025-2032) By Type

Table 89: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 90: South America Market Value (USD Million) (2025-2032) By Country

Table 91: South America Market Value (USD Million) (2025-2032) By Type

Table 92: South America Market Value (USD Million) (2025-2032) By Application

Table 93: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 94: Middle East & Africa Market Value (USD Million) (2025-2032) By Type

Table 95: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 96: Global Progestogen-releasing IUD Market Volume (K) By Region

Table 97: Global Progestogen-releasing IUD Market Share (%) By Region (2025-2032)

Table 98: North America Market Volume (K) (2025-2032) By Country

Table 99: North America Market Volume (K) (2025-2032) By Type

Table 100: North America Market Volume (K) (2025-2032) By Application

Table 101: Europe Market Volume (K) (2025-2032) By Country

Table 102: Europe Market Volume (K) (2025-2032) By Type

Table 103: Europe Market Volume (K) (2025-2032) By Application

Table 104: Asia Pacific Market Volume (K) (2025-2032) By Country

Table 105: Asia Pacific Market Volume (K) (2025-2032) By Type

Table 106: Asia Pacific Market Volume (K) (2025-2032) By Application

Table 107: South America Market Volume (K) (2025-2032) By Country

Table 108: South America Market Volume (K) (2025-2032) By Type

Table 109: South America Market Volume (K) (2025-2032) By Application

Table 110: Middle East & Africa Market Volume (K) (2025-2032) By Country

Table 111: Middle East & Africa Market Volume (K) (2025-2032) By Type

Table 112: Middle East & Africa Market Volume (K) (2025-2032) By Application

Table 113: Research Programs/Design For This Report

Table 114: Key Data Information From Secondary Sources

Table 115: Key Data Information From Primary Sources

FAQs

1. What is the current Progestogen-releasing IUD market size?

The Progestogen-releasing IUD market size reached roughly USD 1.2 billion in 2023, driven by expanding contraceptive use in North America and Europe, alongside rising awareness in emerging economies. This figure reflects sales of both hormonal and copper‑based intrauterine devices worldwide.

2. What is the growth forecast for the market?

Analysts highlight the Progestogen-releasing IUD market's future outlook, projecting expansion at a 5.6 % CAGR from 2024 to 2032 and reaching roughly USD 1.9 billion by the period’s end. Growth is anchored in demographic shifts and supportive policies.

3. Which factors are driving market expansion?

Key drivers include increasing demand for long‑acting reversible contraception, favorable reimbursement policies, rising female workforce participation that prioritizes convenience, and expanding clinical evidence of safety and efficacy. Additionally, telehealth integration accelerates product adoption across urban and rural settings.

4. What challenges could impede market growth?

Challenges comprise limited access in low‑income regions, cultural resistance to intrauterine devices, stringent regulatory approvals that prolong time‑to‑market, and provider training gaps affecting insertion quality, potentially hindering patient confidence. Furthermore, competition from newer hormonal implants and oral contraceptives pressures pricing strategies.

5. Which regions lead the Progestogen-releasing IUD market?

North America remains the largest contributor, accounting for about 45 % of global sales, driven by high awareness and insurance coverage. Europe follows with strong public‑health programs, while Asia‑Pacific shows the fastest growth rate due to expanding middle‑class populations.

6. Who are the top companies operating in this space?

Leading players include Bayer AG, Merck KGaA, Teva Pharmaceutical Industries, Allergan (now part of AbbVie), and CooperSurgical. These firms dominate through extensive product portfolios, strategic partnerships, and robust distribution networks that secure market share across multiple continents.

7. What future opportunities exist for the market?

Future opportunities arise from integrating digital health platforms for remote monitoring, developing smaller‑diameter devices for adolescents, and expanding into untapped emerging markets with government‑backed family‑planning initiatives. Personalized hormone release profiles also present a niche for premium segments.

8. How is technology influencing product development?

Advances in polymer science enable longer‑lasting hormone reservoirs, while 3‑D printing accelerates prototype testing and customization. Smart IUD concepts embed sensors to track placement and release kinetics, potentially reshaping clinical follow‑up and improving patient adherence.

9. What is the regulatory landscape for Progestogen-releasing IUDs?

Regulators such as the FDA, EMA, and Asian health authorities classify these devices as Class III medical products, requiring rigorous clinical trials and post‑market surveillance. Recent guidances emphasize real‑world evidence, which may streamline approvals but increase data‑submission complexity.

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Progestogen-releasing IUD Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	5.20 billion
Revenue forecast in 2033	8.80 billion
Growth rate	CAGR of 6.8% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Type, Application
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Bayer AG; CooperSurgical Inc; DKT International; Mona Lisa NV; Pregna International Limited; Prosan International BV; Abviee Inc; Eurogine, S.L.; Viatris Inc; Mona Lisa N.V.,
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options